Current treatment of chronic hepatitis C in China: Dilemma and potential problems

Qun-Ying Han, Zheng-Wen Liu

Qun-Ying Han, Zheng-Wen Liu, Department of Infectious Diseases, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China

Author contributions: Han QY and Liu ZW conceived the paper and collected the material; Liu ZW wrote the manuscript; both authors have approved the final version to be published.

Conflict-of-interest statement: The authors declare that there is no conflict of interest related to this paper.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Zheng-Wen Liu, MD, PhD, Professor, Department of Infectious Diseases, First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yanta Road, Xi’an 710061, Shaanxi Province, China. liuzhengwen@medmail.com.cn Telephone: +86-18991232331 Fax: +86-29-85252580

Received: March 1, 2016 Peer-review started: March 2, 2016 First decision: March 21, 2016 Revised: April 3, 2016 Accepted: April 20, 2016 Article in press: April 20, 2016 Published online: May 21, 2016

Abstract

Major advances have been made in the treatment of chronic hepatitis C virus (HCV) infection with the advent of direct-acting antiviral agents (DAAs). China has the most cases of HCV infection worldwide, but none of the DAAs has been approved in mainland China so far, and interferon (IFN)-α-based treatment remains the standard of care. HCV patients without response or with contraindications to IFN-based therapy have no alternative options. However, many patients buy DAAs, especially the generic forms of sofosbuvir, from other countries or areas. Under these circumstances, the use of these drugs may cause many predictable and unpredictable problems in ethics, law and medical practice. Given the obstacles of legal accessibility to DAAs and the potential problems of obtaining and using DAAs in China, the early launching of the DAAs in China or the legalization of buying drugs from areas outside China and using these drugs in China is an urgent issue and needs to be dealt with as soon as possible, in the interest of the patients.

Key words: Hepatitis C virus infection; Treatment; Direct-acting antiviral agent; Generics; China

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This article describes the current treatment situation of chronic hepatitis C virus infection in China and discusses the potential problems pertinent to the access and the use of direct-acting antiviral agents (DAAs), especially the use of generic DAAs from various sources.

Han QY, Liu ZW. Current treatment of chronic hepatitis C in China: Dilemma and potential problems. World J Gastroenterol 2016; 22(19): 4615-4618. Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i19/4615.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i19.4615

INTRODUCTION

Infection with hepatitis C virus (HCV) is a leading
cause of liver disease. Worldwide, an estimated 130-170 million people have HCV infection, and China has the most cases of HCV infection worldwide, with an estimated 29.8 million people\textsuperscript{[1]}. A high proportion of people with HCV infection have developed advanced chronic liver diseases, including chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC).

The primary goal of treating chronic HCV infection is to achieve a sustained virologic response (SVR), which is defined as the absence of serum HCV RNA 12-24 wk after cessation of treatment. Patients achieving an SVR are considered cured in that 99% of patients who achieve an SVR remain undetectable for virus during long-term follow-up\textsuperscript{[2]}. Achievement of SVR is associated with improved clinical outcomes. Pegylated interferon (Peg-IFN)-α 2a or 2b in combination with ribavirin (RBV) has been the standard of care for chronic HCV infection. However, treatment with Peg-IFN-α and RBV has limited efficacy. For instance, 48 wk of Peg-IFN and RBV therapy may achieve SVR in only 40% of patients with HCV genotype 1 infection\textsuperscript{[3]}. Significant adverse events may accompany the duration of treatment\textsuperscript{[3,5]}, resulting in poor adherence and premature treatment discontinuation. Moreover, patients with decompensated liver disease, patients with HIV/HCV co-infection, patients who have comorbidity such as heart disease or chronic kidney diseases, patients who have had renal failure and renal transplantation, and patients who have undergone liver transplantation for HCV-associated liver disease may be contraindicated to or ineligible for the regimen of IFN and RBV. Patients who have a null or low response to the regimen of IFN and RBV and patients who are unwilling to take the drugs have no alternative effective treatments. Therefore, novel treatments that have more potent antiviral activity and fewer adverse effects and are eligible and compatible for patients with complex comorbidity in real life settings are urgently required.

Fortunately, major advances have been made in the treatment of chronic HCV infection, with the advent of direct-acting antiviral agents (DAAs) in recent years. Many regimens free of IFN or free of both IFN and RBV have been devised based on combination of new DAAs. These new regimens provide excellent efficacy with higher SVR rates and good safety profile with fewer side effects, and are of shorter duration of treatment. The patients also have a better treatment experience, higher adherence to treatment, and substantial improvement of health-related quality of life during treatment\textsuperscript{[6]}. DAA combination regimens also provide high SVR rates in patients with various HCV genotypes, disease conditions and treatment experiences, including cirrhosis associated with HCV genotype 1\textsuperscript{[7,8]}, liver and kidney transplant recipients\textsuperscript{[9]}. HCV-genotype-1-infected patients with compensated cirrhosis who had not achieved SVR after successive treatments with Peg-IFN and protease-inhibitor regimens\textsuperscript{[10]}, and treatment-naive and treatment-experienced patients co-infected with HIV and HCV genotypes 1-4\textsuperscript{[11]}.

**CURRENT TREATMENT OF CHRONIC HCV INFECTION IN CHINA**

Because of the unavailability of the novel DAAs, IFN-α or Peg-IFN-α in combination with RBV remains the current standard of care for chronic HCV infection in mainland China. Under these circumstances, HCV patients, especially some important and difficult to treat HCV patients, such as nonresponders to IFN and RBV treatment and those with relapse; patients with renal failure or heart disease; patients intolerant to the adverse events of and with contraindications to INF and RBV; patients with HCV-related cirrhosis and/or HCC; and patients with HIV/HCV co-infection have no other treatment options. In reality, however, the patients themselves are pragmatic. They try to seek help from other sources and find ways possible to obtain the drugs for the treatment of their disease. The high cost used to be one of the obstacles for some patients because of the unaffordability, but the cost is not an issue with the launching of generic drugs in some countries such as India. The price of the generic drugs is much lower than their brand-name counterparts. As a result, many HCV patients have bought or are going to buy DAAs, mainly sofosbuvir, a “blockbuster drug”, from various regions or countries such as India and Bangladesh through different means, including through brokers, relatives and friends who have the opportunity to buy the drugs. The HCV patient population using DAAs, mainly sofosbuvir, from the above-mentioned sources is rapidly increasing in China.

**DISCUSSION**

Undoubtedly, most patients may benefit from the use of these drugs. Ethically and responsibly, doctors would be pleased to see that the patients have access to effective medicines and the probable cure of their disease. However, some problems may be encountered.

First, none of the DAAs including sofosbuvir, whether generics or brand name, has been approved by the China Food and Drug Administration. In this respect, the use of these drugs appears to be illegal in China. There is a similar but not identical example. Lu Yong, a Chinese man, who was diagnosed with chronic myeloid leukemia when he was aged 34 years in 2002, was arrested, jailed and then released by the police authorities in China early this year because of purchasing the Indian generic drug imatinib mesylate for himself and other patients. Although he appeared to be accused of selling “fake drugs”, he knows nothing about the reasons for either being arrested or being released\textsuperscript{[12]}. It is suggested that there are some legal issues and gaps.
Second, physicians may feel frustrated and embarrassed when they are consulted by patients with chronic HCV infection regarding the treatment of the disease. The doctors may tell the patients that there are many new drugs that are effective and have fewer adverse effects and may be suitable for their condition when they advise patients who are unsuitable for IFN and RBV, but none of the drugs is lawfully available in China. Of course, the doctors can let the patients wait for the availability of these drugs. However, some of the patients, such as those with decompensated liver disease and those awaiting organ transplantation, cannot wait because of the rapid progress of their disease and its life-threatening potential. Another situation is that the patients consult doctors about using drugs that they have bought from other countries, mostly from illegal sources and by illegal means, and the drugs may thus be regarded as “fake drugs”. Additionally, the quality of the drugs may also not be guaranteed. In this situation, the doctors may place themselves at risk because they appear to guide their patients to use “fake drugs”.

Third, because of the lack of other DAs for rational combination, most of the patients take sofosbuvir in combination with RBV and some patients even use sofosbuvir alone for the treatment of their HCV infection with various treatment durations, irrespective of the HCV genotypes involved, the underlying liver disease (hepatitis or cirrhosis) and comorbidity. In reality, the situation may be rather more complex than expected. HCV genotype 1 infection accounts for most cases of HCV infection in China, but there are also other genotypes in China, including 2, 3 and 6 [13].

Although the combination of sofosbuvir and RBV is a pan-genotypic regimen and may be applied for HCV genotypes 1-6, and this regimen remains the standard of care for genotypes 2 and 3, its efficacy was suboptimal in patients with HCV genotype 1, with an SVR of 54% for genotype 1b treatment-naïve hepatitis and 60% for genotype 1 treatment-naïve cirrhosis after 24 wk of treatment [14]. In the United States, the regimen of sofosbuvir and RBV for 24 wk in patients with genotype 1 infection is not recommended because of the longer treatment duration and lower expected SVR rates compared with other regimens [15].

The efficacy of this regimen for treatment-experienced genotypes 2 and 3 infection, with or without cirrhosis, was also suboptimal, with an SVR of 72% for genotype 2 treatment-experienced cirrhosis after 12 wk of treatment, an SVR of 77% for genotype 3 treatment-experienced hepatitis after 24 wk of treatment, and an SVR of 60% for genotype 3 treatment-experienced cirrhosis after 24 wk of treatment [14]. Based on these data, it is indicated that a proportion of patients with HCV genotype 1 or genotypes 2 and 3 treatment-experienced hepatitis or cirrhosis is using an non-optimal regimen for treatment. Therefore, it is anticipated that higher non-response and relapse rates may result from the use of this regimen.

Another concern is the possibility of treatment-emergent variants that may confer resistance to the antiviral treatment, although sofosbuvir has high genetic barriers to resistance [14]. Of note, a DAA used as monotherapy is not recommended because of the strong likelihood of treatment failure and the potential to induce resistance [15].

Moreover, the drug safety and drug-drug interactions pertinent to the use of sofosbuvir and RBV or sofosbuvir alone cannot be completely ignored. Sofosbuvir has a good safety profile and few drug-drug interactions. However, the safety of sofosbuvir in patients with some comorbidity, such as severe renal impairment (an estimated glomerular filtration rate < 30 mL/min/1.73 m²) or end-stage renal disease on dialysis, is not well established, in that the levels of sofosbuvir and its metabolite are substantially elevated in such patients [15]. In contrast, co-administration of P-glycoprotein inhibitors, including anticonvulsants such as phenobarbital, antimycobacterials such as rifampin, ritonavir-boosted tipranavir, and St John’s Wort can decrease sofosbuvir concentrations [16]. Additionally, although sofosbuvir is not supposed to have significant pharmacological interactions with tacrolimus or cyclosporine [17], unexplained tacrolimus/cyclosporine reduction, which needs dosage adjustment, was observed in transplant recipients during sofosbuvir/RBV treatment for severe HCV infection recurrence. This raises the importance of awareness in the post-transplant HCV-recurrence setting when sofosbuvir is administered [18]. All these may place the patients with some comorbidity in unsafe conditions or bring new problems for the retreatment of patients if necessary.

CONCLUSION

As doctors, we hope for early launching of the DAs, not only sofosbuvir but also other agents that can be rationally combined with sofosbuvir, in China, and the legalization of buying drugs including generic drugs from areas outside China and using these drugs in China, without further delay, in the interest of the patients. Presently, regulations concerning the usage of drugs, including generic drugs from other areas and international routes, should be established by the health authorities in China to meet the urgent needs. In the long run, China’s health authorities need to reform fully their drug import policy and distribution system to satisfy legitimately and sensibly the therapeutic requirement of patients. In particular, the authorities need to guarantee the timely availability of novel drugs, even if they may be generics, for the urgent need of severely ill patients to improve survival and quality of life. At the same time, doctors may become confident to advise the use of such drugs without fear of violating the law or regulations concerning the quality of the drugs. We wish for the early arrival of a time when patients can easily and legally have access to effective drugs, and doctors can lawfully and
unimpeachably play their role in the treatment of HCV infection.

REFERENCES

1. Hajarizadeh B, Grebely J, Dore JJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107]

2. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abengoa A, Pessoa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alpha-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601 [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]

3. Mchutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 590-593 [PMID: 19625712 DOI: 10.1056/NEJMoa0808010]

4. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins B, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800 [PMID: 15791680 DOI: 10.1002/hep.20659]

5. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglio AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatology 2007; 46: 420-431 [PMID: 17196293 DOI: 10.1016/j.jhep.2006.10.009]

6. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient’s journey with chronic hepatitis C from interferon plus ribavirin to sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 and fibrosis. Hepatology 2015; 62: 1004-1012 [PMID: 26096332 DOI: 10.1002/hep.27937]

7. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1888 [PMID: 25722263 DOI: 10.1002/hep.27770]

8. Bourlière M, Bronowicki JP, de Ledingen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, Mchutchison JG, Marcellin P, Habersetzer F, Gyudayer D, Grange JD, Loustaunau-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397-404 [PMID: 25773757 DOI: 10.1016/S1473-3099(15)70050-2]

9. Molina JM, Orkin C, Isom DF, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggero A, Ni L, Svarovskiai E, Brainard D, Subramanian GM, Mchutchison JG, Puoti M, Rockstroh JK. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTO2-1): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385: 1098-1106 [PMID: 25659285 DOI: 10.1016/S0140-6736(14)62483-1]

10. The first person acting as purchasing agency of anti-cancer drugs: still does not know the reasons being arrested and then released. February 1, 2015. Available from: URL: http://news.21cn.com/domestic/jinrirdian/a/2015/0201/10/28958693.shtml (accessed July 26, 2015)

11. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, Wei L, Chen CJ, Sievert W, Yuan Y, Li H. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int 2015; 9: 378-390 [PMID: 26071238 DOI: 10.1007/s12072-015-9629-x]

12. Horner SM, Naggie S. Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog 2015; 11: e1004854 [PMID: 26087286 DOI: 10.1371/journal.ppat.1004854]

13. Chopra S, Muir AJ. Treatment regimens for chronic hepatitis C virus genotype 1. Available from: URL: http://www.uptodate.com/contents/treatment-regimens-for-chronic-hepatitis-c-virus-genotype-1-source=see_link (accessed July 26, 2015)

14. Bill L. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med 2015; 23: 92-96 [PMID: 26200709]

15. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 476-487 [PMID: 24387618 DOI: 10.1111/apt.12601]

16. Vukotic R, Morelli MC, Pimma AD, Margotti M, Foschi FG, Loggi E, Bernardi M, Andreone P. Letter: calcineurin inhibitor level of chronic hepatitis C virus infection. Clin J. Am Soc Nephrol 2013; 8: 1708-1712 [PMID: 23715047 DOI: 10.2215/CJN.00840313]

17. Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Sofosbuvir and Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523 [PMID: 24209977 DOI: 10.1016/S0140-6736(13)62121-2]

18. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, Mchutchison JG, Membrelo F. Sofosbuvir and ledipasvir fixed-dose combination with or without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523 [PMID: 24209977 DOI: 10.1016/S0140-6736(13)62121-2]

19. Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004-1012 [PMID: 26096332 DOI: 10.1002/hep.27937]

20. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1888 [PMID: 25722263 DOI: 10.1002/hep.27770]

P- Reviewer: Bradrick SS, Stasi C S- Editor: Yu J L- Editor: A E- Editor: Zhang DN
